Koi Biotherapeutics
Koi Biotherapeutics is focused on solving a fundamental challenge in CAR T-cell therapy—the lack of long-term persistence of CAR T-cells post-infusion. Koi has developed a novel CAR-Enhancer protein that selectively targets CAR T-cells and promotes their development into memory cells, thereby enhancing their activity and in vivo persistence and eliminating the need for additional engineering…
-
Hamid Mahini, PhD
Co-Founder & CEO
-
Mohammad Rashidian, PhD
Scientific Founder, Assistant Professor at Dana-Farber Cancer Institute/Harvard Medical School
Nucyrna Therapeutics
Nucyrna Therapeutics aims to address the unmet medical needs in ALS and other CNS disorders through its next-gen RNA-targeting technology. Nucyrna’s oligonucleotide platform can target both Nuclear & Cytoplasmic RNA, enabling unique RNA-targeting capacities for addressing complex pathology. Demonstrating a remarkable therapeutic index profile in CNS, the company is focused on neurodegenerative diseases.
-
Damon Wang, PhD
CEO
-
Joseph Klim, PhD
Director of Neuroscience
-
Jonathan Watts, PhD
Scientific Founder & Advisor
-
Robert Brown, MD, DPhil
Scientific Founder & Advisor
-
Evangelos Kiskinis, PhD
Scientific Founder & Advisor
Sphinxion Therapeutics
Sphinxion Therapeutics leverages decades of academic research to bring forward therapeutic options targeting the sphingolipid metabolic pathway as a treatment for rare and common fibrotic diseases. Preliminary animal models in two specific diseases have been effectively treated with AAV gene therapy.
-
Julie Saba, MD, PhD
The John & Edna Beck Chair in Pediatric Cancer Research, UCSF
-
Biren Shah, MBA
Advisor, Revolution Medicines
Cloverleaf Bio
Cloverleaf Bio has developed a new type of RNA therapeutics, based on tRNAs. Its engineered tRNAs have a broad range of applications including oncology, viral infection, and neurodegenerative disorders. Cloverleaf’s patented tRNAs target core components of the cellular translation machinery—tRNA modifying enzymes—that are essential for disease progression.
-
Austin Draycott, PhD
Co-founder & CEO
-
Cole Lewis, M. Phil
Co-founder & CSO
Eascra Biotech
Eascra Biotech is an early-stage nanomedicine start-up launched in Nov 2021. Its proprietary therapeutic delivery platform can deliver RNA, gene editing, and other therapeutic options to hard-to-penetrate tissues such as cartilage, kidney, brain, and some solid tumors. Eascra is partnering with NASA to advance its science here on earth.
-
Mari Anne Snow
Co-founder & CEO
-
Yupeng Chen, PhD
Co-founder & CSO
Externa
Externa is a platform technology company from the Church and Collins labs that combines synthetic biology, chemistry, and machine learning to bring the power of medicinal chemistry to protein therapeutics with synthetic amino acids. These new-to-nature amino acids give proteins new capabilities, such as irreversible binding, longer stability, or pH-dependent activity.
PathCision Medicine, Inc
PathCision Medicine is harnessing tissue pathology insights to develop new targeted therapies. Built using a translational lens with a multi-omics approach, its proprietary discovery platform uncovers novel therapeutic avenues previously unavailable to patients with complex diseases. PathCision’s leading program is focused on developing a biologic modality for metastasis-selective delivery for multiple indications.
-
Shana Wang
CEO
Tezcat Biosciences, Inc
Tezcat Biosciences is developing a portfolio of protein-drug conjugates to provide therapeutic options for patients harboring mutant RAS cancers. Tezcat’s current portfolio consists of conjugates combining its proprietary protein carrier with established drug payloads. To-date, Tezcat’s drug development has been supported by academic collaborations and government awards.
-
Alexander Efron, MBA
Business Advisor
General Biologics, Inc
General Biologics is a protein engineering company with a platform technology that targets therapeutic proteins to red blood cell precursors and mature red blood cells. This enhances plasma half-life and shields therapeutic proteins from the immune system, and when needed, will activate red blood cell production without side effects.
-
Jeffrey C. Way
President & Chief Executive Officer
-
R. Rogers Yocum
Chief Financial Officer
-
Pamela A. Silver
Scientific Advisor
Ilios Therapeutics, Inc
Ilios Therapeutics utilizes a proprietary modular chemistry platform to develop first-in-class multi-valent small molecules modulating multiple complementary mechanisms involved in neurodegenerative diseases.
-
Dr. Fares Nigim
Founder
-
Luca Giani
Founder & CEO
InGel Therapeutics
InGel Therapeutics is developing innovative cell-based therapy to bring back light to patients who suffer from all forms of retinal degeneration. Our lead program, IGT001, is a mutation-agnostic approach to Retinitis Pigmentosa, with future expansion opportunities including dry AMD and Glaucoma.
-
Pierre Dromel
Co-founder & Chief Executive Officer
-
Deepti Singh
Co-founder & Chief Scientific Officer
-
Patrick Jiang
Co-founder & Chief Business Officer
-
Michael Young
Co-founder & Chairman of SAB
RiverWalk Therapeutics
Riverwalk Therapeutics is a preclinical drug development company developing adenosine A2 receptor inhibitors for treating metastatic cancer. Our lead molecule, RW-108, has demonstrated significant potency reducing primary tumors (70%), extending lifespan (>40%), reducing bone metastases (98%), and depleting circulating tumor cells in the blood (78%) and bone marrow (98%).
-
Johanna Vincze Webb
President
-
Jean X. Jiang
Chief Science Officer & Chairman of the Board